In conclusion, our study provides novel knowledge on the immune modulation occurring during tumor-targeted therapy with BRAFi leading to a T cell-inflamed TME characterized by the infiltration of cytotoxic T cells, inflammatory monocytes and activated cDC1 and cDC2. Here, MPPE1 is linked to neoplasm.